Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Creators: name: Tentori, Cristina A
name: Zhao, Lin P
name: Tinterri, Benedetta
name: Strange, Kathryn E
name: Zoldan, Katharina
name: Dimopoulos, Konstantinos
name: Feng, Xingmin
name: Riva, Elena
name: Lim, Benjamin
name: Simoni, Yannick
name: Murthy, Vidhya
name: Hayes, Madeline J
name: Poloni, Antonella
name: Padron, Eric
name: Cardoso, Bruno A
name: Cross, Michael
name: Winter, Susann
name: Santaolalla, Aida
name: Patel, Bhavisha A
name: Groarke, Emma M
name: Wiseman, Daniel H
name: Jones, Katy
name: Jamieson, Lauren
name: Manogaran, Charles
name: Daver, Naval
name: Gallur, Laura
name: Ingram, Wendy
name: Ferrell, P Brent
name: Sockel, Katja
name: Dulphy, Nicolas
name: Chapuis, Nicolas
name: Kubasch, Anne S
name: Olsnes, Astrid M
name: Kulasekararaj, Austin
name: De Lavellade, Hugues
name: Kern, Wolfgang
name: Van Hemelrijck, Mieke
name: Bonnet, Dominique
name: Westers, Theresia M
name: Freeman, Sylvie
name: Oelschlaegel, Uta
name: Valcarcel, David
name: Raddi, Marco G
name: Grønbæk, Kirsten
name: Fontenay, Michaela
name: Loghavi, Sanam
name: Santini, Valeria
name: Almeida, Antonio M
name: Irish, Jonathan M
name: Sallman, David A
name: Young, Neal S
name: van de Loosdrecht, Arjan A
name: Adès, Lionel
name: Della Porta, Matteo G
name: Cargo, Catherine
name: Platzbecker, Uwe
name: Kordasti, Shahram
name: consortium, i4MDS
Publisher: name: The Francis Crick Institute
Year: 2024
Subjects: classificationCode: Tumour Biology
subject: Tumour Biology
classificationCode: Stem Cells
subject: Stem Cells
classificationCode: Human Biology & Physiology
subject: Human Biology &amp; Physiology

description: Advancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models have substantively advanced risk stratification, recent revelations have emphasized the pivotal role of immune dysregulation within the bone marrow milieu during MDS evolution. Nonetheless, immunotherapy for MDS has not experienced breakthroughs seen in other malignancies, partly attributable to the absence of an immune classification that could stratify patients toward optimally targeted immunotherapeutic approaches. A pivotal obstacle to establishing "immune classes" among MDS patients is the absence of validated accepted immune panels suitable for routine application in clinical laboratories. In response, we formed International Integrative Innovative Immunology for MDS (i4MDS), a consortium of multidisciplinary experts, and created the following recommendations for standardized methodologies to monitor immune responses in MDS. A central goal of i4MDS is the development of an immune score that could be incorporated into current clinical risk stratification models. This position paper first consolidates current knowledge on MDS immunology. Subsequently, in collaboration with clinical and laboratory specialists, we introduce flow cytometry panels and cytokine assays, meticulously devised for clinical laboratories, aiming to monitor the immune status of MDS patients, evaluating both immune fitness and identifying potential immune "risk factors." By amalgamating this immunological characterization data and molecular data, we aim to enhance patient stratification, identify predictive markers for treatment responsiveness, and accelerate the development of systems immunology tools and innovative immunotherapies.